Biocept, Inc.
BIOCQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.36M | 6.59M | 25.86M | 40.75M | 57.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.36M | 6.59M | 25.86M | 40.75M | 57.21M |
| Cost of Revenue | 15.66M | 21.14M | 28.44M | 34.16M | 39.65M |
| Gross Profit | -14.31M | -14.55M | -2.58M | 6.58M | 17.56M |
| SG&A Expenses | 14.82M | 17.03M | 23.24M | 25.14M | 26.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.51M | 43.52M | 57.84M | 65.72M | 72.57M |
| Operating Income | -33.16M | -36.93M | -31.98M | -24.97M | -15.36M |
| Income Before Tax | -30.73M | -37.15M | -32.21M | -25.23M | -15.73M |
| Income Tax Expenses | -125.00K | -125.00K | -125.00K | 125.00K | 125.00K |
| Earnings from Continuing Operations | -30.61 | -37.02 | -32.09 | -25.35 | -15.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.61M | -37.02M | -32.09M | -25.35M | -15.85M |
| EBIT | -33.16M | -36.93M | -31.98M | -24.97M | -15.36M |
| EBITDA | -31.33M | -35.22M | -30.33M | -23.31M | -13.74M |
| EPS Basic | -50.60 | -64.92 | -56.70 | -44.92 | -28.27 |
| Normalized Basic EPS | -31.77 | -40.72 | -35.57 | -27.94 | -17.53 |
| EPS Diluted | -50.88 | -65.20 | -56.83 | -45.05 | -28.27 |
| Normalized Diluted EPS | -31.77 | -40.72 | -35.57 | -27.94 | -17.53 |
| Average Basic Shares Outstanding | 2.76M | 2.29M | 2.26M | 2.25M | 2.20M |
| Average Diluted Shares Outstanding | 2.76M | 2.29M | 2.26M | 2.25M | 2.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |